Stopping Graft-Versus-Host Disease in the Intestines
Preventing GVHD by inhibition of alloantigen presentation in the gut
This research looks for new ways to prevent a serious complication called Graft-Versus-Host Disease (GVHD) in the gut for people receiving bone marrow transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11116862 on NIH RePORTER |
What this research studies
Bone marrow transplants are life-saving treatments for blood cancers and other severe conditions, but a major challenge is Graft-Versus-Host Disease (GVHD), especially when it affects the digestive system. Current treatments for GVHD often broadly suppress the immune system and are not always effective, leading to severe and sometimes fatal outcomes. This project aims to understand how certain cells in the small intestine, called antigen-presenting cells, start GVHD. By identifying these specific cells and the factors that activate them, we hope to find new, more targeted ways to prevent this serious complication.
Who could benefit from this research
Good fit: This research is most relevant to patients who have received or will receive an allogeneic bone marrow transplant for blood cancers, bone marrow failure, or immunodeficiency diseases.
Not a fit: Patients who are not undergoing bone marrow transplantation or who have conditions unrelated to Graft-Versus-Host Disease would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and safer ways to prevent severe and often fatal Graft-Versus-Host Disease, particularly in the digestive tract, for patients undergoing bone marrow transplantation.
How similar studies have performed: This project builds on preliminary data and uses cutting-edge techniques to explore new pathways, suggesting a novel approach with foundational support.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Hill, Geoffrey Roger — Fred Hutchinson Cancer Center
- Study coordinator: Hill, Geoffrey Roger
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.